NL195051C - Recombinant-pokkenvirussen, immunologische samenstellingen die een recombinant-pokkenvirus omvatten en werkwijze voor het tot expressie brengen van het DNA in een recombinant-pokkenvirus. - Google Patents
Recombinant-pokkenvirussen, immunologische samenstellingen die een recombinant-pokkenvirus omvatten en werkwijze voor het tot expressie brengen van het DNA in een recombinant-pokkenvirus. Download PDFInfo
- Publication number
- NL195051C NL195051C NL8820679A NL8820679A NL195051C NL 195051 C NL195051 C NL 195051C NL 8820679 A NL8820679 A NL 8820679A NL 8820679 A NL8820679 A NL 8820679A NL 195051 C NL195051 C NL 195051C
- Authority
- NL
- Netherlands
- Prior art keywords
- virus
- recombinant
- dna
- pox
- gene
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims description 260
- 238000000034 method Methods 0.000 title claims description 46
- 239000000203 mixture Substances 0.000 title claims description 14
- 230000001900 immune effect Effects 0.000 title claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 163
- 244000144977 poultry Species 0.000 claims description 108
- 206010037742 Rabies Diseases 0.000 claims description 78
- 239000000427 antigen Substances 0.000 claims description 57
- 108091007433 antigens Proteins 0.000 claims description 57
- 102000036639 antigens Human genes 0.000 claims description 57
- 238000012360 testing method Methods 0.000 claims description 57
- 238000011081 inoculation Methods 0.000 claims description 45
- 241000271566 Aves Species 0.000 claims description 44
- 244000052769 pathogen Species 0.000 claims description 38
- 230000014509 gene expression Effects 0.000 claims description 37
- 229960005486 vaccine Drugs 0.000 claims description 35
- 230000001717 pathogenic effect Effects 0.000 claims description 32
- 230000028993 immune response Effects 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- 241001465754 Metazoa Species 0.000 claims description 27
- 241000700626 Cowpox virus Species 0.000 claims description 25
- 201000003740 cowpox Diseases 0.000 claims description 24
- 241000124008 Mammalia Species 0.000 claims description 20
- 210000002966 serum Anatomy 0.000 claims description 20
- 238000002255 vaccination Methods 0.000 claims description 20
- 230000004044 response Effects 0.000 claims description 18
- 108090000288 Glycoproteins Proteins 0.000 claims description 16
- 102000003886 Glycoproteins Human genes 0.000 claims description 15
- 238000010790 dilution Methods 0.000 claims description 13
- 239000012895 dilution Substances 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 238000002965 ELISA Methods 0.000 claims description 11
- 230000000405 serological effect Effects 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 6
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 238000006386 neutralization reaction Methods 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 2
- 230000005847 immunogenicity Effects 0.000 claims description 2
- 238000012606 in vitro cell culture Methods 0.000 claims description 2
- 230000010076 replication Effects 0.000 claims description 2
- 230000036449 good health Effects 0.000 claims 1
- 239000013612 plasmid Substances 0.000 description 134
- 235000013594 poultry meat Nutrition 0.000 description 105
- 239000012634 fragment Substances 0.000 description 96
- 210000004027 cell Anatomy 0.000 description 72
- 108020004414 DNA Proteins 0.000 description 58
- 102000053602 DNA Human genes 0.000 description 58
- 239000013598 vector Substances 0.000 description 44
- 230000006798 recombination Effects 0.000 description 32
- 108091034117 Oligonucleotide Proteins 0.000 description 31
- 241000283973 Oryctolagus cuniculus Species 0.000 description 31
- 238000005215 recombination Methods 0.000 description 27
- 108010005774 beta-Galactosidase Proteins 0.000 description 25
- 238000010276 construction Methods 0.000 description 25
- 230000029087 digestion Effects 0.000 description 25
- 208000015181 infectious disease Diseases 0.000 description 25
- 239000000047 product Substances 0.000 description 25
- 101710154606 Hemagglutinin Proteins 0.000 description 24
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 24
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 24
- 101710176177 Protein A56 Proteins 0.000 description 24
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 24
- 239000000185 hemagglutinin Substances 0.000 description 18
- 238000011144 upstream manufacturing Methods 0.000 description 18
- 102000004594 DNA Polymerase I Human genes 0.000 description 17
- 108010017826 DNA Polymerase I Proteins 0.000 description 17
- 241000287828 Gallus gallus Species 0.000 description 16
- 235000013330 chicken meat Nutrition 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 16
- 239000011159 matrix material Substances 0.000 description 16
- 241000700647 Variola virus Species 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 241000714266 Bovine leukemia virus Species 0.000 description 14
- 241000711450 Infectious bronchitis virus Species 0.000 description 14
- 102000005936 beta-Galactosidase Human genes 0.000 description 14
- 239000006166 lysate Substances 0.000 description 13
- 238000013519 translation Methods 0.000 description 13
- 241000283690 Bos taurus Species 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 241000287219 Serinus canaria Species 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 206010046865 Vaccinia virus infection Diseases 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 11
- 208000007089 vaccinia Diseases 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 10
- 108010061100 Nucleoproteins Proteins 0.000 description 10
- 206010022000 influenza Diseases 0.000 description 10
- 230000036961 partial effect Effects 0.000 description 10
- 102000011931 Nucleoproteins Human genes 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 229920002477 rna polymer Polymers 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 241000282326 Felis catus Species 0.000 description 8
- 208000010359 Newcastle Disease Diseases 0.000 description 8
- 241000700584 Simplexvirus Species 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 238000001114 immunoprecipitation Methods 0.000 description 8
- 108091081024 Start codon Proteins 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 230000002458 infectious effect Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 241000712461 unidentified influenza virus Species 0.000 description 7
- 241001135961 Amsacta moorei entomopoxvirus Species 0.000 description 6
- 101100462495 Caenorhabditis elegans rsa-1 gene Proteins 0.000 description 6
- 101150118742 NP gene Proteins 0.000 description 6
- 241001494479 Pecora Species 0.000 description 6
- 241000711798 Rabies lyssavirus Species 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 235000015278 beef Nutrition 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 235000013601 eggs Nutrition 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 5
- 241000178270 Canarypox virus Species 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 5
- 210000003837 chick embryo Anatomy 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 101150069452 z gene Proteins 0.000 description 5
- 101150110188 30 gene Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 241000286209 Phasianidae Species 0.000 description 4
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 4
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000013256 coordination polymer Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
- 241000711404 Avian avulavirus 1 Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 101150082239 G gene Proteins 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 239000012888 bovine serum Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000012447 hatching Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000002729 polyribosome Anatomy 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 230000037380 skin damage Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000700570 unidentified entomopoxvirus Species 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 244000291564 Allium cepa Species 0.000 description 2
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 2
- 101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- 101150097493 D gene Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 101150039660 HA gene Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000590492 Homo sapiens Nuclear fragile X mental retardation-interacting protein 1 Proteins 0.000 description 2
- 241000255777 Lepidoptera Species 0.000 description 2
- 241000721703 Lymantria dispar Species 0.000 description 2
- 102100032428 Nuclear fragile X mental retardation-interacting protein 1 Human genes 0.000 description 2
- KUGRPPRAQNPSQD-UHFFFAOYSA-N OOOOO Chemical compound OOOOO KUGRPPRAQNPSQD-UHFFFAOYSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 240000007643 Phytolacca americana Species 0.000 description 2
- 101710182846 Polyhedrin Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 101150003725 TK gene Proteins 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 210000001643 allantois Anatomy 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 210000003555 cloaca Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 101150036031 gD gene Proteins 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229960000380 propiolactone Drugs 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 241000670670 Amsacta Species 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 241000700572 Entomopoxvirinae Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 241000567412 Estigmene acrea Species 0.000 description 1
- 101150057091 FP1 gene Proteins 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 1
- 101000713585 Homo sapiens Tubulin beta-4A chain Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 102100035304 Lymphotactin Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000238814 Orthoptera Species 0.000 description 1
- 241000287127 Passeridae Species 0.000 description 1
- 101100271190 Plasmodium falciparum (isolate 3D7) ATAT gene Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 241000714233 Rous-associated virus type 1 Species 0.000 description 1
- 241000287231 Serinus Species 0.000 description 1
- 241000287181 Sturnus vulgaris Species 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 102100036788 Tubulin beta-4A chain Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- -1 fter Species 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010211 hemagglutination inhibition (HI) assay Methods 0.000 description 1
- 210000000087 hemolymph Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 240000001854 junco Species 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000004237 neck muscle Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229940049155 rabies serum Drugs 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 101150116497 sacm1l gene Proteins 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9071187A | 1987-08-28 | 1987-08-28 | |
| US9071187 | 1987-08-28 | ||
| US11033587A | 1987-10-20 | 1987-10-20 | |
| US11033587 | 1987-10-20 | ||
| US18605488A | 1988-04-25 | 1988-04-25 | |
| US18605488 | 1988-04-25 | ||
| US23439088A | 1988-08-23 | 1988-08-23 | |
| US23439088 | 1988-08-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL8820679A NL8820679A (nl) | 1989-07-03 |
| NL195051C true NL195051C (nl) | 2003-07-01 |
Family
ID=27492413
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8820679A NL195051C (nl) | 1987-08-28 | 1988-08-24 | Recombinant-pokkenvirussen, immunologische samenstellingen die een recombinant-pokkenvirus omvatten en werkwijze voor het tot expressie brengen van het DNA in een recombinant-pokkenvirus. |
| NL300130C NL300130I2 (nl) | 1987-08-28 | 2003-07-09 | Recombinant-pokkenvirussen, immunologische samenstellingen die een recombinant-pokkenvirus omvatten en werkwijze voor het tot expressie brengen van het DNA in een recombinant-pokkenvirus. |
| NL300139C NL300139I1 (nl) | 1987-08-28 | 2003-11-25 | Recombinant-pokkenvirussen, immunologische samenstellingen die een recombinant-pokkenvirus omvatten en werkwijze voor het tot expressie brengen van het DNA in een recombinant-pokkenvirus. |
| NL300138C NL300138I2 (nl) | 1987-08-28 | 2003-11-25 | Recombinant-pokkenvirussen, immunologische samenstellingen die een recombinant-pokkenvirus omvatten en werkwijze voor het tot expressie brengen van het DNA in een recombinant-pokkenvirus. |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL300130C NL300130I2 (nl) | 1987-08-28 | 2003-07-09 | Recombinant-pokkenvirussen, immunologische samenstellingen die een recombinant-pokkenvirus omvatten en werkwijze voor het tot expressie brengen van het DNA in een recombinant-pokkenvirus. |
| NL300139C NL300139I1 (nl) | 1987-08-28 | 2003-11-25 | Recombinant-pokkenvirussen, immunologische samenstellingen die een recombinant-pokkenvirus omvatten en werkwijze voor het tot expressie brengen van het DNA in een recombinant-pokkenvirus. |
| NL300138C NL300138I2 (nl) | 1987-08-28 | 2003-11-25 | Recombinant-pokkenvirussen, immunologische samenstellingen die een recombinant-pokkenvirus omvatten en werkwijze voor het tot expressie brengen van het DNA in een recombinant-pokkenvirus. |
Country Status (17)
| Country | Link |
|---|---|
| JP (3) | JP3348156B2 (de) |
| KR (1) | KR970011149B1 (de) |
| AR (1) | AR241939A1 (de) |
| AT (1) | AT408549B (de) |
| AU (2) | AU2427588A (de) |
| BE (1) | BE1002134A5 (de) |
| CH (2) | CH679934A5 (de) |
| DE (4) | DE10399031I1 (de) |
| DK (1) | DK175904B1 (de) |
| FR (1) | FR2621487B1 (de) |
| GB (1) | GB2217718B (de) |
| IL (1) | IL87581A0 (de) |
| IT (1) | IT1229484B (de) |
| LU (2) | LU90951I2 (de) |
| NL (4) | NL195051C (de) |
| NZ (1) | NZ225970A (de) |
| WO (1) | WO1989003429A1 (de) |
Families Citing this family (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5338683A (en) * | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US5505941A (en) * | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| DE10399031I1 (de) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
| US5286639A (en) * | 1987-09-16 | 1994-02-15 | Nippon Zeon Co., Ltd. | Recombinant avipoxvirus |
| DE3813093A1 (de) * | 1988-04-19 | 1989-11-09 | Immuno Ag | Rekombinantes plasmid, verfahren zum herstellen eines rekombinanten avipoxvirus, rekombinantes avipoxvirus und dessen verwendung |
| US5631154A (en) * | 1988-06-10 | 1997-05-20 | Therion Biologics, Incorporated | Self assembled, defective, non-self-propagating lentivirus particles |
| DE68912441T2 (de) * | 1988-06-24 | 1994-05-11 | British Tech Group | Nichtessentielle Geflügelpockenvirus-Regionen. |
| US5093258A (en) * | 1988-08-26 | 1992-03-03 | Therion Biologics Corporation | Recombinant fowlpox virus and recombination vector |
| CA2001001A1 (en) * | 1988-10-21 | 1990-04-21 | Matthew M. Binns | Fowlpox virus promoter |
| US6248333B1 (en) | 1990-04-04 | 2001-06-19 | Health Research Inc. | Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD) |
| US5204243A (en) * | 1990-02-14 | 1993-04-20 | Health Research Incorporated | Recombinant poxvirus internal cores |
| MY109299A (en) * | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| US5514375A (en) * | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
| FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| US5756102A (en) * | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
| US5503834A (en) * | 1990-11-20 | 1996-04-02 | Virogenetics Corporation | Measles virus recombinant poxvirus vaccine |
| IE71643B1 (en) * | 1990-11-20 | 1997-02-26 | Virogenetics Corp | A recombinant poxviral vaccine for canine distemper |
| US5759841A (en) * | 1990-11-20 | 1998-06-02 | Virogenetics Corporation | Immunological composition of measles virus utilizing recombinant poxvirus |
| US6309647B1 (en) | 1999-07-15 | 2001-10-30 | Aventis Pasteur | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants |
| US5338679A (en) * | 1991-01-08 | 1994-08-16 | Her Majesty The Queen In Right Of Canada, As Represented By National Research Council Canada And Forestry Canada | Vertebrate poxvoris expression vector under the control of entomopoxvirus spheroidin gene promoter |
| US5766597A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Malaria recombinant poxviruses |
| US5756101A (en) * | 1991-07-01 | 1998-05-26 | Pasteur Merieux Serums Et Vaccins | Malaria recombinant poxvirus |
| US5863542A (en) * | 1991-03-07 | 1999-01-26 | Virogenetics Corporation | Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts |
| EP0575491B1 (de) * | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Gentechnologisch hergestellter stamm für impfstoffe |
| US5766598A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
| CA2106464A1 (en) * | 1991-03-20 | 1992-09-21 | Enzo Paoletti | Malaria recombinant poxvirus vaccine |
| EP1156102A1 (de) * | 1991-06-14 | 2001-11-21 | Virogenetics Corporation | Rekombinanter hiv-spezifischer Impfstoff aus Poxvirus |
| JPH06509235A (ja) * | 1991-07-26 | 1994-10-20 | ヴァイロジェネティクス コーポレイション | 伝染性ファブリキウス嚢病ウイルス組換えポックスウイルスワクチン |
| ES2212795T3 (es) * | 1991-08-26 | 2004-08-01 | Baxter Healthcare S.A. | Virus de la viruela de las aves de corral recombinante. |
| US5443831A (en) * | 1991-10-29 | 1995-08-22 | University Of Delaware | Gene encoding glycoprotein B of Infectious Laryngotracheitis Virus |
| US6127163A (en) * | 1992-01-13 | 2000-10-03 | Syntro Corporation | Recombinant swinepox virus |
| US6328975B1 (en) | 1992-01-13 | 2001-12-11 | Syntro Corporation | Recombinant swinepox virus |
| US6033904A (en) * | 1992-01-13 | 2000-03-07 | Syntro Corporation | Recombinant swinepox virus |
| US6497882B1 (en) | 1992-01-13 | 2002-12-24 | Syntro Corporation | Recombinant swinepox virus |
| AU680609B2 (en) * | 1992-01-13 | 1997-08-07 | Virogenetics Corporation | Marek's disease virus recombinant poxvirus vaccine |
| US6251403B1 (en) | 1992-01-13 | 2001-06-26 | Syntro Corporation | Recombinant swinepox virus |
| US5869312A (en) * | 1992-01-13 | 1999-02-09 | Syntro Corporation | Recombinant swinepox virus |
| AU5138293A (en) * | 1992-09-21 | 1994-04-12 | Chiron Viagene, Inc. | Recombinant retroviral vector against felv and/or fiv |
| CA2156423A1 (en) * | 1993-02-26 | 1994-09-01 | Mark D. Cochran | Recombinant fowlpox viruses and uses thereof |
| AU727278B2 (en) * | 1993-02-26 | 2000-12-07 | Syntro Corporation | Recombinant fowlpox viruses and uses thereof II |
| US5925358A (en) * | 1993-02-26 | 1999-07-20 | Syntro Corporation | Recombinant fowlpox viruses and uses thereof |
| US6136318A (en) * | 1993-02-26 | 2000-10-24 | Cochran; Mark D. | Recombinant fowlpox viruses and uses thereof |
| US5496731A (en) * | 1993-03-25 | 1996-03-05 | Xu; Hong-Ji | Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy |
| US5843742A (en) * | 1994-12-16 | 1998-12-01 | Avigen Incorporated | Adeno-associated derived vector systems for gene delivery and integration into target cells |
| EP0753581A1 (de) | 1995-07-10 | 1997-01-15 | Immuno Ag | Verbesserte rekombinante eukaryotische zytoplasmatische Viren, Methode ihrer Herstellung und ihrer Verwendung als Impfstoffe |
| US5858373A (en) * | 1995-12-01 | 1999-01-12 | Virogenetics Corporation | Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them |
| EP0954593A1 (de) | 1996-07-25 | 1999-11-10 | Therion Biologics Corporation | Rekombinantes pockenvirus für die immunsierung gegen tumorassoziierte antigene. |
| US6106825A (en) * | 1997-05-07 | 2000-08-22 | University Of Florida | Entomopoxvirus-vertebrate gene delivery vector and method |
| AU3910097A (en) * | 1997-08-05 | 1999-03-01 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Live recombinant vaccine comprising inefficiently or non-replicating vir us |
| US6248582B1 (en) * | 1997-10-08 | 2001-06-19 | Imran Khan | Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV |
| JPH11165762A (ja) | 1997-12-01 | 1999-06-22 | Lintec Corp | チップ体搬送用カバーテープおよび封止構造体 |
| US20020147143A1 (en) | 1998-03-18 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
| US6221349B1 (en) | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
| EP1141313A2 (de) | 1998-12-31 | 2001-10-10 | Chiron Corporation | Verbesserte exprimierung von hiv polypeptiden und herstellung von virusähnliche partikeln |
| US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| AU5773500A (en) | 1999-06-28 | 2001-01-31 | Board Of Trustees Of The University Of Illinois, The | Inhibitors of memapsin 2 and use thereof |
| WO2001062778A2 (en) | 2000-02-23 | 2001-08-30 | Smithkline Beecham Biologicals S.A. | Tumour-specific animal proteins |
| EP1319069B1 (de) | 2000-06-28 | 2008-05-21 | Corixa Corporation | Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs |
| ATE499948T1 (de) | 2001-01-12 | 2011-03-15 | Novartis Vaccines & Diagnostic | Nukleinsäure mukosale immunisierung |
| CN1258596C (zh) * | 2001-03-08 | 2006-06-07 | 阿克佐诺贝尔公司 | 基于野兔痘的载体疫苗 |
| JP4499311B2 (ja) * | 2001-04-27 | 2010-07-07 | シャープ株式会社 | 放送受信端末 |
| JP2005504513A (ja) | 2001-05-09 | 2005-02-17 | コリクサ コーポレイション | 前立腺癌の治療及び診断のための組成物及び方法 |
| JP4302513B2 (ja) | 2001-07-05 | 2009-07-29 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 抗原性ｂ型ｈｉｖポリペプチドおよび／または抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用 |
| US7211659B2 (en) | 2001-07-05 | 2007-05-01 | Chiron Corporation | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
| DK1581119T3 (da) | 2001-12-17 | 2013-05-13 | Corixa Corp | Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme |
| KR101110889B1 (ko) | 2003-01-06 | 2012-02-20 | 코릭사 코포레이션 | 특정의 아미노알킬 글루코사미나이드 포스페이트 화합물 및그들의 용도 |
| US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| CA2525825A1 (en) | 2003-05-15 | 2005-01-27 | Chiron Corporation | Hiv polynucleotides and polypeptides derived from botswana mj4 |
| US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| AU2005287505A1 (en) | 2004-09-22 | 2006-03-30 | Biosynexus Incorporated | Staphylococcal immunogenic compositions |
| EP2360175B1 (de) | 2005-11-22 | 2014-07-16 | Novartis Vaccines and Diagnostics, Inc. | Norovirus und sapovirus virusähnliche partikel (vlps) |
| WO2007120368A2 (en) | 2006-01-09 | 2007-10-25 | The Regents Of The University Of California | Immunostimulatory combinations for vaccine adjuvants |
| EP2441470B1 (de) | 2006-03-14 | 2014-05-07 | Oregon Health and Science University | Verfahren zur Erzeugung einer Immunantwort auf Tuberculosis |
| CA2678404C (en) | 2007-02-28 | 2019-03-19 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Brachyury polypeptides and methods for use |
| AU2008314485B9 (en) | 2007-10-15 | 2015-02-26 | Jingang Medicine (Australia) Pty Ltd | Expression system for modulating an immune response |
| US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| BRPI1005670A8 (pt) | 2009-01-05 | 2017-12-26 | Epitogenesis Inc | composições adjuvantes e processos de uso. |
| WO2010099472A2 (en) | 2009-02-27 | 2010-09-02 | The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services | Spanx-b polypeptides and their use |
| CN102713629B (zh) | 2009-11-20 | 2016-02-24 | 俄勒冈健康科学大学 | 用于检测结核分枝杆菌感染的方法 |
| US20130052221A1 (en) | 2010-02-26 | 2013-02-28 | The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services | Dna-protein vaccination protocols |
| US9795658B2 (en) | 2010-04-20 | 2017-10-24 | Admedus Vaccines Pty Ltd | Expression system for modulating an immune response |
| US9428565B2 (en) | 2011-01-31 | 2016-08-30 | The General Hospital Corporation | Treatment and bioluminescent visualization using multimodal TRAIL molecules |
| WO2012151272A2 (en) | 2011-05-02 | 2012-11-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| MX2013013627A (es) | 2011-06-21 | 2014-04-25 | Oncofactor Corp | Composiciones y metodos para la terapia y diagnostico de cancer. |
| JP6499446B2 (ja) | 2011-06-24 | 2019-04-10 | エピットジェネシス・インコーポレーテッド | 抗原特異的免疫モジュレーターとして選択担体、ビタミン、タンニンおよびフラボノイドの組み合わせを含有する医薬組成物 |
| US20150004144A1 (en) | 2011-12-02 | 2015-01-01 | The General Hospital Corporation | Differentiation into brown adipocytes |
| EP2890720B1 (de) | 2012-08-30 | 2019-07-17 | The General Hospital Corporation | Zusammensetzungen und verfahren zur behandlung von krebs |
| WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
| US20150224181A1 (en) | 2012-09-14 | 2015-08-13 | The United States Of America As Represented By The Secretary Department Of Health And Human Se | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
| CA2909706C (en) | 2013-04-17 | 2023-02-14 | Genzyme Corporation | Use of an il17 inhibitor for treating and preventing macular degeneration |
| US9988617B2 (en) | 2013-05-21 | 2018-06-05 | President And Fellows Of Harvard College | Engineered heme-binding compositions and uses thereof |
| US10172916B2 (en) | 2013-11-15 | 2019-01-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating heart failure with agonists of hypocretin receptor 2 |
| SG11201606101WA (en) | 2014-02-06 | 2016-08-30 | Genzyme Corp | Compositions and methods for treating and preventing macular degeneration |
| EP3194446B1 (de) | 2014-09-18 | 2022-10-26 | Cedars-Sinai Medical Center | Zusammensetzungen und verfahren zur behandlung von fibrose |
| WO2016154010A1 (en) | 2015-03-20 | 2016-09-29 | Makidon Paul | Immunogenic compositions for use in vaccination against bordetella |
| EP3283529B1 (de) | 2015-04-17 | 2023-06-07 | The General Hospital Corporation | Wirkstoffe, systeme und verfahren zur behandlung von krebs |
| WO2016172479A1 (en) | 2015-04-22 | 2016-10-27 | Cedars-Sinai Medical Center | Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes |
| ES2959642T3 (es) | 2015-05-13 | 2024-02-27 | The Us Secretary Of The Department Of Health And Human Services | Metodos y composiciones para inducir una respuesta inmunitaria mediante construcciones con elementos conservados |
| WO2016196366A1 (en) | 2015-05-29 | 2016-12-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Extension of replicative lifespan in diseases of premature aging using p53 isoforms |
| EP3313863B1 (de) | 2015-06-29 | 2020-12-23 | The Board of Trustees of the Leland Stanford Junior University | Degronfusionskonstrukte und verfahren zur steuerung der proteinproduktion |
| EP3386593A4 (de) | 2015-12-09 | 2019-07-24 | Admedus Vaccines Pty Ltd | Immunmodulierende zusammensetzung zur behandlung |
| NZ749593A (en) | 2016-06-20 | 2025-10-31 | Univ Leland Stanford Junior | Circular rnas and their use in immunomodulation |
| WO2018018082A1 (en) | 2016-07-26 | 2018-02-01 | The Australian National University | Immunostimulatory compositions and uses therefor |
| US12416015B2 (en) | 2017-09-15 | 2025-09-16 | The Board Of Trustees Of The Leland Stanford Junior University | Multiplex production and barcoding of genetically engineered cells |
| US10917454B1 (en) | 2019-08-01 | 2021-02-09 | Rohde & Schwarz Gmbh & Co. Kg | System and method for ATC voice quality assurance |
| EP4419684A1 (de) | 2021-10-21 | 2024-08-28 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Retroelementerzeugte transkriptionsfaktorköder |
| WO2023077147A2 (en) | 2021-11-01 | 2023-05-04 | Pellis Therapeutics, Inc. | T-cell vaccines for patients with reduced humoral immunity |
| CA3237482A1 (en) | 2021-11-03 | 2023-05-11 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Precise genome editing using retrons |
| WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| EP4499839A1 (de) | 2022-03-25 | 2025-02-05 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Verfahren zur beurteilung der manipulierten retron-aktivität und verwendungen davon |
| WO2023183589A1 (en) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Rt-dna fidelity and retron genome editing |
| WO2023183627A1 (en) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna |
| WO2024020346A2 (en) | 2022-07-18 | 2024-01-25 | Renagade Therapeutics Management Inc. | Gene editing components, systems, and methods of use |
| WO2024044673A1 (en) | 2022-08-24 | 2024-02-29 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Dual cut retron editors for genomic insertions and deletions |
| WO2024044723A1 (en) | 2022-08-25 | 2024-02-29 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| WO2024233791A1 (en) | 2023-05-11 | 2024-11-14 | Seelos Therapeutics, Inc. | Methods of treating neurodegenerative disorders |
| WO2025081042A1 (en) | 2023-10-12 | 2025-04-17 | Renagade Therapeutics Management Inc. | Nickase-retron template-based precision editing system and methods of use |
| WO2025155753A2 (en) | 2024-01-17 | 2025-07-24 | Renagade Therapeutics Management Inc. | Improved gene editing system, guides, and methods |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK489481A (da) * | 1980-11-10 | 1982-05-11 | Searle & Co | Plasmidvektor og frmgangsmaade til fremstilling deraf |
| US4603112A (en) * | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| WO1984002077A1 (en) * | 1982-11-30 | 1984-06-07 | Us Health | Process for producing poxvirus recombinants for expression of foreign genes |
| FR2563434B1 (fr) * | 1984-04-25 | 1986-07-25 | Transgene Sa | Vaccin contre la rage et procede pour sa preparation |
| EP0190254A4 (de) * | 1984-07-05 | 1987-03-09 | Genex Corp | Kloniertes gen, verfahren zu dessen herstellung und seine verwendung. |
| DD235669A1 (de) * | 1985-03-26 | 1986-05-14 | Akad Wissenschaften Ddr | Verfahren zur herstellung eines blv-kodierten huellproteins |
| EP0218625B1 (de) * | 1985-03-29 | 1995-04-05 | Btg International Limited | Spike-protein des virus der infektiösen bronchitis |
| AU6170486A (en) * | 1985-08-23 | 1987-02-26 | Advanced Genetics Research Institute | Defective viral vaccines |
| AU607399B2 (en) * | 1985-09-09 | 1991-03-07 | Cetus Corporation | Infectious recombinant virus vaccine for feline leukemia |
| NZ217645A (en) * | 1985-09-25 | 1991-11-26 | Oncogen | Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations |
| AU602875B2 (en) * | 1985-12-18 | 1990-11-01 | British Technology Group Limited | Newcastle disease virus gene clones |
| AU8075787A (en) * | 1986-09-22 | 1988-04-07 | Australian National University, The | Recombinant poxviruses |
| WO1988002022A1 (en) * | 1986-09-22 | 1988-03-24 | Commonwealth Scientific And Industrial Research Or | Recombinant poxviruses |
| EP0261940A3 (de) * | 1986-09-23 | 1989-07-05 | Applied Biotechnology, Inc. | Pseudorabies-Impfstoffe und DNS-Vektoren zur Rekombination mit Poxviren |
| EP0284416B1 (de) * | 1987-03-27 | 1995-02-22 | Nippon Zeon Co., Ltd. | Rekombinantes Avipoxvirus |
| DE10399031I1 (de) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
| GB8724885D0 (en) * | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
| FR2632863B2 (fr) * | 1987-10-29 | 1990-08-31 | Transgene Sa | Virus du fowlpox recombinant et vaccins derives de ces virus |
| DE68912441T2 (de) * | 1988-06-24 | 1994-05-11 | British Tech Group | Nichtessentielle Geflügelpockenvirus-Regionen. |
| AU625584B2 (en) * | 1989-03-08 | 1992-07-16 | Health Research Inc. | Recombinant poxvirus host selection system |
| KR100372934B1 (ko) * | 1990-09-25 | 2003-12-24 | 캔탑 파마슈티칼스 리서취 리미티드 | 형질 상보성 세포주에 의해 생성된 바이러스 결손 백신 |
-
1987
- 1987-08-24 DE DE2003199031 patent/DE10399031I1/de active Pending
- 1987-08-24 DE DE2003199032 patent/DE10399032I1/de active Pending
-
1988
- 1988-08-24 KR KR1019890700753A patent/KR970011149B1/ko not_active Expired - Lifetime
- 1988-08-24 CH CH1444/91A patent/CH679934A5/de not_active IP Right Cessation
- 1988-08-24 WO PCT/US1988/002816 patent/WO1989003429A1/en not_active Ceased
- 1988-08-24 CH CH1652/89A patent/CH679933A5/de not_active IP Right Cessation
- 1988-08-24 NL NL8820679A patent/NL195051C/nl not_active IP Right Cessation
- 1988-08-24 JP JP50771588A patent/JP3348156B2/ja not_active Expired - Lifetime
- 1988-08-24 AU AU24275/88A patent/AU2427588A/en not_active Abandoned
- 1988-08-24 AT AT0900788A patent/AT408549B/de not_active IP Right Cessation
- 1988-08-24 DE DE2002199049 patent/DE10299049I1/de active Pending
- 1988-08-24 DE DE3890874A patent/DE3890874C5/de not_active Expired - Lifetime
- 1988-08-24 GB GB8908921A patent/GB2217718B/en not_active Expired - Lifetime
- 1988-08-28 IL IL87581A patent/IL87581A0/xx not_active IP Right Cessation
- 1988-08-29 NZ NZ225970A patent/NZ225970A/xx unknown
- 1988-08-29 BE BE8800978A patent/BE1002134A5/fr not_active IP Right Cessation
- 1988-08-29 AR AR88311787A patent/AR241939A1/es active
- 1988-08-29 FR FR888811334A patent/FR2621487B1/fr not_active Expired - Lifetime
- 1988-08-29 IT IT8821772A patent/IT1229484B/it active
-
1989
- 1989-04-27 DK DK198902036A patent/DK175904B1/da active Protection Beyond IP Right Term
-
1995
- 1995-04-05 AU AU16288/95A patent/AU690210B2/en not_active Expired
-
2001
- 2001-10-09 JP JP2001311076A patent/JP2002186494A/ja active Pending
-
2002
- 2002-03-15 JP JP2002071416A patent/JP3826055B2/ja not_active Expired - Lifetime
- 2002-09-04 LU LU90951C patent/LU90951I2/fr unknown
-
2003
- 2003-07-09 NL NL300130C patent/NL300130I2/nl unknown
- 2003-09-05 LU LU91039C patent/LU91039I2/fr unknown
- 2003-11-25 NL NL300139C patent/NL300139I1/nl unknown
- 2003-11-25 NL NL300138C patent/NL300138I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL195051C (nl) | Recombinant-pokkenvirussen, immunologische samenstellingen die een recombinant-pokkenvirus omvatten en werkwijze voor het tot expressie brengen van het DNA in een recombinant-pokkenvirus. | |
| US5505941A (en) | Recombinant avipox virus and method to induce an immune response | |
| US5174993A (en) | Recombinant avipox virus and immunological use thereof | |
| KR0179994B1 (ko) | 칠면조의 재조합 포진바이러스 및 이로부터 유도된 생존상태의 벡터 백신 | |
| US5093258A (en) | Recombinant fowlpox virus and recombination vector | |
| CN105567648B (zh) | 用于免疫接种水禽物种的重组禽疱疹病毒载体和疫苗 | |
| JPH084508B2 (ja) | 組み換えワクチニアウイルス | |
| US5651972A (en) | Use of recombinant swine poxvirus as a live vaccine vector | |
| JP2000501930A (ja) | 組換体ポックスウイルス―ネコ感染性腹膜炎ウイルス、その組成物およびそれらの製造および使用方法 | |
| CN107771216B (zh) | 重组mdv1及其用途 | |
| Tripathy | Swinepox virus as a vaccine vector for swine pathogens | |
| WO1994024268A1 (en) | Recombinant avian adenovirus vector | |
| WO2007115385A2 (en) | Transfer plasmidic vector and recombinant canarypox virus | |
| EP0471457A2 (de) | Herpesvirus-Vektor, der ein Epitope des Maul- und Klauenseuchenviruses exprimiert | |
| NZ527940A (en) | Leporipox-based vector vaccines | |
| AU761321B2 (en) | Recombinant viruses, vaccines containing them and in vitro cell cultures thereof | |
| CA1341403C (en) | Recombinant a vipox virus | |
| DK176068B1 (da) | Rekombinant kanaripoxvirus og anvendelsen af samme | |
| DK175980B1 (da) | Recombinante vacciniavira og anvendelsen af samme | |
| DK176165B1 (da) | Rekombinant fjerkræpoxvirus samt anvendelsen af samme | |
| AU725985B2 (en) | Recombinant virus | |
| Carlson | Development and application of genetically engineered viral vaccines of poultry | |
| IE882620L (en) | Recombinant avipox virus | |
| AU676042B2 (en) | Recombinant avian adenovirus vector |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| NP1 | Patent granted (not automatically) | ||
| KC1 | Grant of a supplementary protection certificate |
Free format text: 300138, 20080824, EXPIRES: 20130823 Spc suppl protection certif: 300138 Filing date: 20080824 Expiry date: 20130823 |
|
| KC1 | Grant of a supplementary protection certificate |
Free format text: 300130, 20080824, EXPIRES: 20130823 Spc suppl protection certif: 300130 Filing date: 20080824 Expiry date: 20130823 |
|
| V4 | Discontinued because of reaching the maximum lifetime of a patent |
Effective date: 20080824 |
|
| SPCX | Supplementary protection certificate expired |
Free format text: PRODUCT NAME: RECOMBINANT KANARIEPOKKENVIRUS-FELV (RECOMBINANT KANARIEPOKKENV IRUS DAT EXOGEEN DNA UIT FELV BEVAT EN TOT EXPRESSIE BRENGT); REGISTRATION NO/DATE: EU/2/00/019/001 - EU/2/00/019/004 20000413 Spc suppl protection certif: C300130 Filing date: 20030709 Expiry date: 20080824 Extension date: 20130823 Free format text: PRODUCT NAME: INFLUENZA A/EQUI-2/KENTUCKY/94 RECOMBINANT KANARIEPOKKENVIRUS EN INFLUENZA A/EQUI-2/NEWMARKET/2/93 RECOMBINANT KANARIEPOKKEN- VIRUS; REGISTRATION NO/DATE: EU/2/03/037/001 - EU/2/03/037/004 20030306 Spc suppl protection certif: C300138 Filing date: 20031125 Expiry date: 20080824 Extension date: 20130823 |